FATE THERAPEUTICS INC Accumulated Other Comprehensive Income
FATE THERAPEUTICS INC (FATE) had Accumulated Other Comprehensive Income of -$117.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-13
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$117.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$77.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $116.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $153.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$117.00K 10-Q · filed 2026-08-13 |
| 2026-03-31 | -$77.00K 10-Q · filed 2026-05-13 |
| 2025-12-31 | $116.00K 10-Q · filed 2026-08-13 |
| 2025-09-30 | $153.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $62.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $191.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $268.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $835.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$422.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | -$194.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $15.00K 10-K · filed 2025-03-05 |
| 2023-09-30 | -$499.00K 10-Q · filed 2023-11-08 |
| 2023-06-30 | -$587.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$646.00K 10-Q · filed 2023-05-03 |
| 2022-12-31 | -$1.85M 10-K · filed 2024-02-26 |
| 2022-09-30 | -$3.25M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$3.38M 10-Q · filed 2022-08-03 |
| 2022-03-31 | -$2.85M 10-Q · filed 2022-05-04 |
| 2021-12-31 | -$762.00K 10-K · filed 2023-02-28 |
| 2021-09-30 | -$73.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | -$86.00K 10-Q · filed 2021-08-04 |
| 2021-03-31 | -$260.00K 10-Q · filed 2021-05-05 |
| 2020-12-31 | $70.00K 10-K · filed 2022-02-28 |
| 2020-09-30 | $312.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $623.00K 10-Q · filed 2020-08-05 |
| 2020-03-31 | $142.00K 10-Q · filed 2020-05-11 |
| 2019-12-31 | $22.00K 10-K · filed 2021-02-24 |
| 2019-09-30 | $51.00K 10-Q · filed 2019-11-05 |
| 2019-06-30 | $93.00K 10-Q · filed 2019-08-06 |
| 2018-12-31 | -$2.00K 10-K · filed 2020-03-02 |
| 2018-09-30 | -$14.00K 10-Q · filed 2018-11-01 |
| 2018-06-30 | -$15.00K 10-Q · filed 2018-08-06 |
| 2018-03-31 | -$13.00K 10-Q · filed 2018-05-10 |
| 2017-12-31 | -$3.00K 10-K · filed 2019-03-05 |
| 2017-09-30 | -$13.00K 10-Q · filed 2017-11-01 |
| 2017-06-30 | -$39.00K 10-Q · filed 2017-08-14 |
| 2017-03-31 | -$34.00K 10-Q · filed 2017-05-15 |
| 2016-12-31 | -$1.00K 10-K · filed 2018-03-05 |
| 2016-09-30 | $3.00K 10-Q · filed 2016-11-07 |
| 2016-06-30 | $11.00K 10-Q · filed 2016-08-08 |
| 2016-03-31 | $14.00K 10-Q · filed 2016-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |